Author:
Chen Manru,Wang Dan,Xu Yanyu,Yang Chenggang
Abstract
AbstractSperm-associated antigen 5 (SPAG5) regulates cancer cell invasion and is involved in the progression of many cancers. However, the role of SPAG5 in endometrial carcinoma (EC) is still unknown. The purpose of this study was to explore the role of SPAG5 in EC and its potential molecular mechanism. The UALCAN tool and cBioPortal were used to analyze the expression and alterations of SPAG5 in EC, respectively. OncoLnc was used for survival analysis. We analyzed the effects of SPAG5 on immune cell infiltration and the expression levels of immune checkpoints. We also overexpressed and knocked down SPAG5 in EC cells to explore the effect of SPAG5 regulation on migration, invasion, apoptosis, and the cell cycle of EC cells. We found that SPAG5 was overexpressed and the SPAG5 gene was often mutated in EC. High SPAG5 expression was significantly associated with poor overall survival in patients with EC. SPAG5 also affected the level of immune cell infiltration in the TIME and the expression of immune checkpoints lymphocyte activating 3 (LAG3) and T cell immunoreceptor with Ig and ITIM domains (TIGIT) in patients with EC. It may also be involved in the immunotherapy response in these patients. In vitro experiments showed that SPAG5 promotes cancer cell migration and invasion. In conclusion, this study lays the foundation for further understanding the molecular mechanisms of EC involving SPAG5 and contributes to diagnosing and managing this disease.
Publisher
Springer Science and Business Media LLC
Reference72 articles.
1. Wang, W., Vilella, F. & Alama, P. Single-cell transcriptomic atlas of the human endometrium during the menstrual cycle. Nat. Med. 26(10), 1644–1653 (2020).
2. Lei, S., Zhang, Q., Yin, F., He, X. & Wang, J. Expression and clinical significance of KLK5-8 in endometrial cancer. Am. J. Transl. Res. 11(7), 4180–4191 (2019).
3. Suhaimi, S. S., Ab Mutalib, N. S. & Jamal, R. Understanding molecular landscape of endometrial cancer through next generation sequencing: What we have learned so far?. Front. Pharmacol. 7, 409 (2016).
4. May, K., Bryant, A., Dickinson, H. O., Kehoe, S. & Morrison, J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst. Rev. 65(1), CD007585 (2015).
5. Howitt, B. E. et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 1(9), 1319–1323 (2015).